Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis

American Journal of Obstetrics and Gynecology

Volumn 187, Issue 6, 2002, Pages 1623-1630

  Kozer, Eran ^a   Nikfar, Shekoufeh ^a   Costei, Adriana ^a   Boskovic, Rada ^a   Nulman, Irena ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Aspirin; Congenital malformations; Meta analysis; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CALCULATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; HUMAN; META ANALYSIS; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0036915413     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.127376     Document Type: Article

References (42)

1. Richards ID. Congenital malformations and environmental influences in pregnancy. Br J Prev Soc Med 1969;23:218-25.
2. Correy JF, Newman NM, Collins JA, Burrows EA, Burrows RF, Curran JT. Use of prescription drugs in the first trimester and congenital malformations. Aust N Z J Obstet Gynaecol 1991;31:340-4.
3. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet 1976;1:1373-5.
4. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989;321:1639-42.
5. Landy HJ, Kessler C, Kelly WK, Weingold AB. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipin antibodies. Am J Perinatol 1992;9:146-51.
6. Passaleva A, Massai G, D’Elios MM, Livi C, Abbate R. Prevention of miscarriage in antiphospholipid syndrome. Autoimmunity 1992;14:121-5.
7. Kwak JYH, Gilman-Sachs A, Beaman KD, Beer AE. Reproductive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: Preconception versus postconception treatment. Am J Obstet Gynecol 1992;166:1787-95.
8. Leitich H, Egarter C, Husslein P, Kaider A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. Br J Obstet Gynaecol 1997;104:450-9.
9. Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 1991;266:260-4.
10. Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) Collaborative Group. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994;343:619-29.
11. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of preeclampsia by early antiplatelet therapy. Lancet 1985;1:840-2.
12. DePass LR, Weaver EV. Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains. J Toxicol Environ Health 1982;10:297-305.
13. Klein KL, Scott WJ, Wilson JG. Aspirin-induced teratogenesis: A unique pattern of cell death and subsequent polydactyly in the rat. J Exp Zool 1981;216:107-12.
14. Robertson RT, Allen HL, Bokelman DL. Aspirin: Teratogenic evaluation in the dog. Teratology 1979;20:313-20.
15. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985;313:347-52.
16. Lynberg MC, Khoury MJ, Lu X, Cocian T. Maternal flu, fever, and the risk of neural tube defects: A population-based case-control study. Am J Epidemiol 1994;140:244-55.
17. Richards ID. A retrospective enquiry into possible teratogenic effects of drugs in pregnancy. Adv Exp Med Biol 1972;27:441-55.
18. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975;4:37-44.
19. Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L. Prenatal exposure to salicylates and gastroschisis: A case-control study. Teratology, 1997;56:241-3.
20. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.
21. Drongowski RA, Smith RK Jr, Coran AG, Klein MD. Contribution of demographic and environmental factors to the etiology of gastroschisis: A hypothesis. Fetal Diagn Ther 1991;6:14-27.
22. Gierup J, Lundkvist K. Gastroschisis: A pilot study of its incidence and the possible influence of teratogenic factors. Z Kinderchir 1979;28:39-42.
23. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-7.
24. Winship KA, Cahal DA, Weber JCP, Griffin JP. Maternal drug histories and central nervous system anomalies. Arch Dis Child 1984;59:1052-60.
25. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008-12.
26. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148-53.
27. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 5th Ed. Baltimore (MD): Williams & Wilkins; 1998.
28. Shepard TH. Catalogue of Teratogenic Agents. 9th Ed. Baltimore (MD): Johns Hopkins University Press; 1998.
29. Karkinen-Jääskeläinen M, Saxén L. Maternal influenza, drug consumption, and congenital defects of the central nervous system. Am J Obstet Gynecol 1974;118:815-8.
30. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1971;1:523-7.
31. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998;57:1-7.
32. Tikkanen J, Heinonen OP. Risk factors for cardiovascular malformations in Finland. Eur J Epidemiol 1990;6:348-56.
33. Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. First-trimester drug use and congenital disorders. Obstet Gynecol 1985;65:451-5.
34. Newman NM, Correy JF, Dudgeon GI. A survey of congenital abnormalities and drugs in a private practice. Aust N Z J Obstet Gynaecol 1977;17:156-9.
35. Siffel C, Czeizel AE. Study of developmental abnormalities and deaths after human zygote exposure. Mutat Res 1995;334:293-300.
36. Turner G, Collins E. Fetal effects of regular salicylate ingestion in pregnancy. Lancet 1975;2:338-9.
37. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension: Italian study of aspirin in pregnancy. Lancet 1993;341:396-400.
38. ECPPA (Estudo Colaborativo para Prevencao da Pre-eclampsia corn Aspirina) Collaborative Group. ECPPA: Randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br J Obstet Gynaecol 1996;103:39-47.
39. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;338:701-5.
40. Golding J. A randomised trial of low dose aspirin for primiparae in pregnancy: The Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol 1998;105:293-9.
41. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574-7.
42. Calzolari E, Volpato S, Bianchi F, et al. Omphalocele and gastroschisis: A collaborative study of five Italian congenital malformation registries. Teratology 1993;47:47-55.